title: Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model.
abstract: OBJECTIVE
  To evaluate differences in strut coverage, inflammation and endothelialization between two second-generation polymer-based drug-eluting stents (DES) in an atherosclerotic rabbit double-injury iliac artery model at 28 days follow-up.
  
  
  RESULTS
  Rabbits with induced atheroma received bilateral iliac artery stents: everolimus-eluting stent (Xience V EES; Abbott Vascular), zotarolimus-eluting stent (Resolute ZES; Medtronic CardioVascular), or bare-metal stent (BMS; MultiLink Vision; Abbott Vascular). After 28 days, total neointimal coverage examined by scanning electron microscopy was >98% for all three stent types. Neointimal thickness above stent struts was decreased by 50% in Xience V EES (0.06 ± 0.01 mm; P = 0.00001) compared with BMS (0.15 ± 0.03 mm) and Resolute ZES (0.12 ± 0.04 mm). Luminal area was largest for Xience V EES (3.79 ± 0.33 mm(2) ; P = 0.0003 for Xience V EES vs. BMS), followed by Resolute ZES (3.46 ± 0.45 mm(2) ; P = 0.083 for Resolute ZES vs. BMS) and BMS (3.07 ± 0.53 mm(2) ). Percentage area stenosis was smallest for Xience V EES (17.23 ± 3.64%; P = 0.00001), while BMS (30.25 ± 7.48%) and Resolute ZES (30.79 ± 7.15%) did not differ. Endothelial monolayer regrowth was significantly lower in Resolute ZES (65 ± 13%) versus BMS (79 ± 11%; P = 0.004). There was no difference between Xience V EES (74 ± 10%) and BMS. Xience V EES was further associated with a lower number of inflammatory cells surrounding the stent struts (7 ± 2 per strut) in comparison to Resolute ZES (15 ± 6; P = 0.0001) and BMS (17 ± 9; P = 0.0005).
  
  
  CONCLUSIONS
  In this atherosclerotic rabbit model, Xience V EES suppressed neointimal thickening better, with normal endothelial regrowth as compared with BMS, and less strut-induced inflammation.
authors.affiliation: Department of Cardiology, Laboratory for Cellular and Molecular Cardiology, Antwerp University Hospital, Antwerp, Belgium.
authors.forename: Christophe J
authors.initials: CJ
authors.lastname: Van Dyck
authors.forename: Vicky Y
authors.initials: VY
authors.lastname: Hoymans
authors.forename: Hidde
authors.initials: H
authors.lastname: Bult
authors.forename: Erik
authors.initials: E
authors.lastname: Fransen
authors.forename: Steven
authors.initials: S
authors.lastname: Haine
authors.forename: Johan M
authors.initials: JM
authors.lastname: Bosmans
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Timmermans
authors.forename: Christiaan J
authors.initials: CJ
authors.lastname: Vrints
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D050197:Atherosclerosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D002317:Cardiovascular Agents / Q000008:administration & dosage; D049109:Cell Proliferation; D004195:Disease Models, Animal; D054855:Drug-Eluting Stents; D042783:Endothelial Cells / Q000648:ultrastructure; D000068338:Everolimus; D007083:Iliac Artery / Q000000981:diagnostic imaging / Q000293:injuries* / Q000648:ultrastructure; D007249:Inflammation / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D008297:Male; D058426:Neointima; D011474:Prosthesis Design; D011817:Rabbits; D011859:Radiography; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D057772:Vascular System Injuries / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus